Sirolimus-based steroid-free maintenance immunosuppression.
Mital
D
D
Rush Medical College, 1725 W. Harrison Street, Suite 161, Chicago, IL 60612-3824, USA.
Podlasek
W
W
Jensik
S C
SC
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D001741:Black or African American; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003920:Diabetes Mellitus / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005260:Female; D006630:Hispanic or Latino; D006801:Humans; D007087:Illinois; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012086:Reoperation; D020123:Sirolimus / Q000627:therapeutic use*; D014019:Tissue Donors / Q000706:statistics & numerical data
D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D020123:Sirolimus; D008775:Methylprednisolone